Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)
4.880
+0.030 (0.62%)
Mar 26, 2026, 3:04 PM CST
SHE:300006 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 926.06 | 1,072 | 836.44 | 846.29 | 559.43 |
Cash & Short-Term Investments | 926.06 | 1,072 | 836.44 | 846.29 | 559.43 |
Cash Growth | -13.62% | 28.18% | -1.16% | 51.28% | 2.67% |
Accounts Receivable | 252.92 | 286.67 | 339.21 | 348.39 | 445.38 |
Other Receivables | 149.15 | 166.75 | 268.73 | 312.52 | 539.13 |
Receivables | 402.08 | 453.42 | 607.94 | 660.9 | 984.51 |
Inventory | 161.33 | 201.7 | 171 | 202.4 | 157.77 |
Prepaid Expenses | - | 11.3 | 3.58 | 2.66 | 4.5 |
Other Current Assets | 31.87 | 31.57 | 27.21 | 33.23 | 20.78 |
Total Current Assets | 1,521 | 1,770 | 1,646 | 1,745 | 1,727 |
Property, Plant & Equipment | 252.18 | 274.92 | 286.97 | 339.92 | 392.49 |
Long-Term Investments | 384.12 | 378.28 | 519.68 | 522.71 | 481.36 |
Goodwill | 44.95 | 44.95 | 32.94 | 32.94 | 32.94 |
Other Intangible Assets | 131.18 | 181.83 | 189.3 | 184.11 | 116.36 |
Long-Term Accounts Receivable | - | - | 34.06 | 32.41 | - |
Long-Term Deferred Tax Assets | 152.39 | 128.24 | 132.35 | 116.58 | 104.62 |
Long-Term Deferred Charges | 55.52 | 40.36 | 27.24 | 63.37 | 62.53 |
Other Long-Term Assets | 33.04 | 37.13 | 22.15 | 17.64 | 9.47 |
Total Assets | 2,575 | 2,856 | 2,891 | 3,055 | 2,927 |
Accounts Payable | 93.48 | 65.62 | 37.9 | 49.63 | 34.26 |
Accrued Expenses | 37.8 | 110.77 | 107.55 | 110.39 | 109.24 |
Short-Term Debt | 179.42 | 242.91 | 113.5 | 121.5 | 130 |
Current Portion of Long-Term Debt | 135.4 | 102.75 | 24 | 58 | - |
Current Portion of Leases | - | 3.65 | 4.26 | 30.2 | 55.41 |
Current Income Taxes Payable | 7.35 | 1.31 | 2.12 | 7.87 | 7.03 |
Current Unearned Revenue | 13.21 | 13.79 | 17.85 | 24.04 | 13.07 |
Other Current Liabilities | 261.82 | 260.8 | 255.09 | 299.51 | 317.8 |
Total Current Liabilities | 728.49 | 801.61 | 562.27 | 701.14 | 666.8 |
Long-Term Debt | 57.2 | 141.45 | 126.5 | 149 | - |
Long-Term Leases | 1.46 | 3.83 | 2.53 | 6.57 | 33.9 |
Long-Term Unearned Revenue | 4.45 | 6.29 | 6.39 | 9.04 | 12.26 |
Long-Term Deferred Tax Liabilities | 19.05 | 19.29 | 19.26 | 4.47 | 1.68 |
Other Long-Term Liabilities | - | - | 51.76 | - | - |
Total Liabilities | 810.65 | 972.47 | 768.71 | 870.22 | 714.65 |
Common Stock | 1,056 | 1,056 | 1,056 | 1,056 | 1,056 |
Additional Paid-In Capital | 1,507 | 1,483 | 1,483 | 1,475 | 1,459 |
Retained Earnings | -750.67 | -501.33 | -414.9 | -406.22 | -358.52 |
Comprehensive Income & Other | -56.23 | -162.53 | -43.77 | - | - |
Total Common Equity | 1,756 | 1,875 | 2,081 | 2,124 | 2,156 |
Minority Interest | 8.18 | 8.04 | 41.51 | 60.52 | 55.78 |
Shareholders' Equity | 1,764 | 1,883 | 2,122 | 2,185 | 2,212 |
Total Liabilities & Equity | 2,575 | 2,856 | 2,891 | 3,055 | 2,927 |
Total Debt | 373.48 | 494.59 | 270.79 | 365.27 | 219.32 |
Net Cash (Debt) | 552.58 | 577.51 | 565.65 | 481.02 | 340.11 |
Net Cash Growth | -4.32% | 2.10% | 17.59% | 41.43% | - |
Net Cash Per Share | 0.52 | 0.55 | 0.54 | 0.46 | 0.34 |
Filing Date Shares Outstanding | 1,056 | 1,056 | 1,056 | 1,056 | 1,056 |
Total Common Shares Outstanding | 1,056 | 1,056 | 1,056 | 1,056 | 1,056 |
Working Capital | 792.85 | 968.49 | 1,084 | 1,044 | 1,060 |
Book Value Per Share | 1.66 | 1.78 | 1.97 | 2.01 | 2.04 |
Tangible Book Value | 1,580 | 1,649 | 1,858 | 1,907 | 2,007 |
Tangible Book Value Per Share | 1.50 | 1.56 | 1.76 | 1.81 | 1.90 |
Buildings | - | 411.75 | 413.99 | 412.67 | 412.67 |
Machinery | - | 652.83 | 646.2 | 674.06 | 664.11 |
Construction In Progress | - | 7 | 2.46 | 3.78 | 4.09 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.